Navigation Links
Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Extension Trial with Tovaxin for Multiple Sclerosis

m, 52-week, parallel-group study, whereby patients will be given five subcutaneous injections at 0, 4, 8, 12 and 24 weeks. The analyses will be performed at the end of the 52-week study to assess the safety and efficacy of Tovaxin. The primary efficacy variable is the cumulative number of gadolinium-enhancing lesions on T1-weighted MRI scans summed over the Week 28, 36, 44, and 52 MRIs. The secondary efficacy variables are the cumulative number of new gadolinium-enhancing lesions at Weeks 28-52, the change in T2-weighted lesion volume, and the annualized relapse rate. As of May 17, 2007, Opexa announced the completion of patient enrollment in a 150-patient Phase IIb safety and efficacy study (TERMS). All patients who complete the trial will be eligible to participate in an optional one-year extension study, in which they will receive Tovaxin under an open-label protocol. The open-label study is being planned under a different protocol that will be submitted to the FDA.

The TERMS study is being conducted at 36 U.S. sites to evaluate the safety and effectiveness of Tovaxin. The TERMS study is registered on the U.S. National Institutes of Health-sponsored website, www.clinicaltrials.gov, where pharmaceutical companies are required to register trials for medicines that will treat serious or life-threatening diseases or conditions. For more information, visit the TERMS website at www.tovaxin.com.

About T-cell Vaccination

For a T-cell vaccine to be effective, it should be able to induce T-cell cytotoxic and/or regulatory immune responses against the pathogenic T-cells. Studies of T-cell vaccine have indicated that T-cell vaccination with peripheral blood-derived autologous myelin-peptide selected T-cells in multiple sclerosis patients resulted in the in vivo induction of CD8+ cytotoxic T-cells and CD4+CD25+FoxP3 Tregs specific for T-cell vaccine. The induction of anti-idiotypic cytotoxic CD8+ effector T-cells and anti-ergotypic CD4+CD25+FoxP3 positive
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Opexa Advances Monocyte Derived Islet Technology to Proof of Principle in stz-induced NOD/SCID Mice
2. Opexa Presents Tovaxin Research at Federation of Clinical Immunology Societies Annual Meeting
3. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Dose Escalation Trial with Tovaxin for Multiple Sclerosis
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
(Date:9/18/2014)... Pa. , Sept. 18, 2014  Iliad Neurosciences, ... approaches to diagnosing and treating Autism Spectrum Disorders (ASD) ... License Agreement with The Research Foundation for The State ... Iliad will provide a new biomarker to identify an ... susceptibility to ASD. This biomarker is expected to be ...
(Date:9/18/2014)... 18, 2014  Decision Resources Group finds that Regeneron,s ... (VEGF) agent for wet AMD, is equally likely to ... Genentech,s Lucentis, which is the standard of care for ... (MCO) directors do not identify a clear clinical or ... than Lucentis to be listed on tier 1 or ...
(Date:9/18/2014)... MARIETTA, Ga. , Sept. 18, 2014 /PRNewswire/ ... ), an integrated developer, processor and marketer of ... human amniotic membrane, announced today that it has ...  Through the agreement, MiMedx will provide its dehydrated ... to be marketed non- exclusively on a private ...
Breaking Medicine Technology:Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 2Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 3Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 2Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 3MiMedx Signs Distribution Agreement With Zimmer 2MiMedx Signs Distribution Agreement With Zimmer 3
... 30 A partnership announced today between Medical City Hospital ... of potential life-saving technology, as Medical City recently helped outfit all ... devices. , , ... The LIFENET device, a unique combination of web, broadband and medical ...
... LONDON , NEW YORK and HAMILTON, Bermuda , ... private equity firm focused on the biotechnology and pharmaceutical industries, announced today ... TDT 067, terbinafine in Transfersomes®, for the topical treatment of onychomycosis (also ... , , ...
Cached Medicine Technology:Medical City Hospital Partners With Dallas Fire-Rescue to Outfit First Mobile Units in Dallas County With Advanced EKG Technology 2Medical City Hospital Partners With Dallas Fire-Rescue to Outfit First Mobile Units in Dallas County With Advanced EKG Technology 3Medical City Hospital Partners With Dallas Fire-Rescue to Outfit First Mobile Units in Dallas County With Advanced EKG Technology 4Medical City Hospital Partners With Dallas Fire-Rescue to Outfit First Mobile Units in Dallas County With Advanced EKG Technology 5Celtic Pharma Announces Initiation of Phase III Trial of TDT 067 for the Treatment of Onychomycosis 2Celtic Pharma Announces Initiation of Phase III Trial of TDT 067 for the Treatment of Onychomycosis 3Celtic Pharma Announces Initiation of Phase III Trial of TDT 067 for the Treatment of Onychomycosis 4
(Date:9/19/2014)... Indiana Fiber Network, LLC (IFN), the ... of its Fiber Transport Services, adding Point of Presence ... establishing a PoP at Cermak, IFN enables interconnect opportunities ... high bandwidth fiber transport service to US and Global ... President of Sales and Marketing August Zehner, establishing a ...
(Date:9/19/2014)... Mount Pleasant Retirement Village has partnered with ... Coach Christi Hall to campus. , Hall’s journey to a ... gaining weight as a result of years of medication. Through ... nutrition. One year later she had lost 50 pounds, lowered ... and cardio. , After joining the YMCA staff, she furthered ...
(Date:9/19/2014)... Newport News, Va. (PRWEB) September 19, 2014 ... at Warwick Forest, a skilled nursing center that offers rehabilitation ... But they will this weekend when a young couple marries ... together and with their combined 140 years of marriage have ... , Sarah Horky, 18, and Dan Eads, 20, may ...
(Date:9/18/2014)... 19, 2014 Today, Zane Benefits, the ... why to switch employees to individual health insurance. ... be more familiar with traditional, group health insurance, there ... employees happier. , The new article provides the ... health insurance rather than group health insurance, and why ...
(Date:9/18/2014)... OR (PRWEB) September 18, 2014 Active ... 50 and older as fully participating members of society ... lifestyle. To celebrate, The Stafford – a boutique retirement ... 97034 – will host two screenings of Cyber-Seniors - ... excited for our residents to watch this great film,” ...
Breaking Medicine News(10 mins):Health News:Indiana Fiber Network Launches Point-Of-Presence in Chicago Data Center at Cermak 2Health News:Mount Pleasant Retirement Village Partners with Atrium Family YMCA 2Health News:Mount Pleasant Retirement Village Partners with Atrium Family YMCA 3Health News:Young Couple Inspired by Residents Of The Gardens At Warwick Forest To Wed There Saturday 2Health News:Young Couple Inspired by Residents Of The Gardens At Warwick Forest To Wed There Saturday 3Health News:Zane Benefits Publishes New Information on Why Employees Are Happier with Individual Health Insurance 2Health News:In Support of Active Aging Week, a Lake Oswego Retirement Community Will Get a Sneak Peek at an Inter-Generational Documentary – Cyber-Seniors 2
... leaders in diagnosing and treating Lyme disease, has launched a new website ... treatment and cure of this highly debated disease. , ... Havertown, PA ... launched a new web site today that is dedicated to giving advanced, ...
... been named president of RetireSafe, a national bipartisan, non-profit ... the options and benefits of retired and retiring Americans ... He has served as a member of the ... providing leadership in multiple areas that engage all facets ...
... patient-centered CERWASHINGTON, May 19 Joining ... the New Democrat Coalition, Tony Coelho, chairman of ... with reporters and announced PIPC,s support for the ... an important step forward for patients and caregivers, ...
... small study , , TUESDAY, May 19 (HealthDay News) -- ... restored blood flow to hearts with blocked arteries for ... reported. , "I think this is very good news ... line and have no options left," said Dr. Douwe ...
... /PRNewswire-FirstCall/ - MDS Nordion, a leading provider of ... its primary supplier, Atomic Energy of Canada Limited ... medical isotopes, primarily molybdenum-99 (Mo-99) used in the ... MDS Nordion that they anticipate the National Research ...
... First, New York State nonprofit outpatient clinics ... Medicaid, Medicaid managed care, Medicare, and insurance billing ... healthiest organization. Millin Associates ( www.millinmedical.com ... for 27 years, provides expanded services and next-generation ...
Cached Medicine News:Health News:Haverford Wellness Center Launches Web Site Devoted to Accurate Diagnosis and Proper Treatment to Cure Lyme Disease 2Health News:Haverford Wellness Center Launches Web Site Devoted to Accurate Diagnosis and Proper Treatment to Cure Lyme Disease 3Health News:RetireSafe Names Thair Phillips as President 2Health News:PIPC Supports New Comparative Effectiveness Research (CER) Bill 2Health News:Stem Cells May Offer New Way to Treat Blocked Arteries 2Health News:Stem Cells May Offer New Way to Treat Blocked Arteries 3Health News:MDS Nordion Provides Update on AECL's Medical Isotope Supply Disruption 2Health News:MDS Nordion Provides Update on AECL's Medical Isotope Supply Disruption 3Health News:Nonprofit Outpatient Clinics and Social Service Agencies Outsource Billing to Increase Profits 2
The new Shandon HistocentreTM 3 is an integral part of the workflow in Histology laboratories, representing a workstation that complements any automatic tissue processor....
Shandon HistoWave is the answer to rapid tissue processing. It reduces time for fixation, tissue processing, decalification, immunochemistry and special stains....
The HypercleanTM 1 is a versatile, durable fume handling station. The Hyperclean 1 fume handling station unit comes complete with one (1) blower unit and one (1) charcoal filter....
... 2 fume containment system ... benchtop equipment. Even large ... inside the Hyperclean 2. ... system unit comes complete with ...
Medicine Products: